Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Receivables: 2022-2024

Historic Change in Receivables for BridgeBio Pharma (BBIO) over the last 3 years, with Dec 2024 value amounting to $3.0 million.

  • BridgeBio Pharma's Change in Receivables rose 21885.71% to $39.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.0 million, marking a year-over-year change of. This contributed to the annual value of $3.0 million for FY2024, which is 119.38% up from last year.
  • According to the latest figures from FY2024, BridgeBio Pharma's Change in Receivables is $3.0 million, which was up 119.38% from -$15.3 million recorded in FY2023.
  • BridgeBio Pharma's Change in Receivables' 5-year high stood at $3.0 million during FY2024, with a 5-year trough of -$15.3 million in FY2023.
  • Moreover, its 3-year median value for Change in Receivables was -$15.2 million (2022), whereas its average is -$9.2 million.
  • Per our database at Business Quant, BridgeBio Pharma's Change in Receivables declined by 1.05% in 2023 and then spiked by 119.38% in 2024.
  • BridgeBio Pharma's Change in Receivables (Yearly) stood at -$15.2 million in 2022, then declined by 1.05% to -$15.3 million in 2023, then skyrocketed by 119.38% to $3.0 million in 2024.